WO2001063293A8 - Proteines et genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie - Google Patents

Proteines et genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie

Info

Publication number
WO2001063293A8
WO2001063293A8 PCT/GB2001/000783 GB0100783W WO0163293A8 WO 2001063293 A8 WO2001063293 A8 WO 2001063293A8 GB 0100783 W GB0100783 W GB 0100783W WO 0163293 A8 WO0163293 A8 WO 0163293A8
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
spis
treatment
diagnosis
detectable
Prior art date
Application number
PCT/GB2001/000783
Other languages
English (en)
Other versions
WO2001063293A2 (fr
WO2001063293A3 (fr
Inventor
Herath Mudiyanselage At Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Original Assignee
Oxford Glycosciences Uk Ltd
Herath Mudiyanselage At Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0004415A external-priority patent/GB0004415D0/en
Application filed by Oxford Glycosciences Uk Ltd, Herath Mudiyanselage At Herath, Rajesh Bhikhu Parekh, Christian Rohlff filed Critical Oxford Glycosciences Uk Ltd
Priority to EP01905991A priority Critical patent/EP1259818A2/fr
Priority to AU2001233954A priority patent/AU2001233954A1/en
Publication of WO2001063293A2 publication Critical patent/WO2001063293A2/fr
Publication of WO2001063293A8 publication Critical patent/WO2001063293A8/fr
Publication of WO2001063293A3 publication Critical patent/WO2001063293A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes et des compositions destinées au criblage, au diagnostic et aux prévisions en matière de schizophrénie, ainsi qu'au suivi de l'efficacité d'un traitement de la schizophrénie, à l'identification de patients susceptibles de réagir à un traitement thérapeutique particulier et au développement de médicaments. L'invention concerne également les caractéristiques associées à la schizophrénie (SF), pouvant être détectées par électrophorèse bidimensionnelle du liquide céphalo-rachidien, du sérum ou du plasma. L'invention concerne en outre des isoformes de protéines associées à la schizophrénie (SPI) que l'on peut détecter dans le liquide céphalo-rachidien, le sérum ou le plasma, des préparations contenant ces isoformes isolées, des anticorps immunospécifiques aux SPI et des kits les comprenant.
PCT/GB2001/000783 2000-02-24 2001-02-23 Proteines et genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie WO2001063293A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01905991A EP1259818A2 (fr) 2000-02-24 2001-02-23 Diagnostic et traitement de la schizophrenie
AU2001233954A AU2001233954A1 (en) 2000-02-24 2001-02-23 Proteins, genes and their use for diagnosis and treatment of schizophrenia

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0004415.6 2000-02-24
GB0004415A GB0004415D0 (en) 2000-02-24 2000-02-24 Proteins and their use for diagnosis and treatment of schizophrenia
US09/750,395 2000-11-28
US75039500A 2000-12-28 2000-12-28

Publications (3)

Publication Number Publication Date
WO2001063293A2 WO2001063293A2 (fr) 2001-08-30
WO2001063293A8 true WO2001063293A8 (fr) 2001-10-18
WO2001063293A3 WO2001063293A3 (fr) 2002-04-11

Family

ID=26243725

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2001/000783 WO2001063293A2 (fr) 2000-02-24 2001-02-23 Proteines et genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie
PCT/GB2001/000792 WO2001062785A2 (fr) 2000-02-24 2001-02-23 Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/000792 WO2001062785A2 (fr) 2000-02-24 2001-02-23 Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie

Country Status (3)

Country Link
EP (2) EP1259607A2 (fr)
AU (2) AU2001237543A1 (fr)
WO (2) WO2001063293A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443123A1 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
EP1408333A3 (fr) * 2001-10-03 2006-10-25 Pfizer Products Inc. Diagnostic et traitement de la maladie d'Alzheimer
US7052849B2 (en) 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
US20030100012A1 (en) * 2001-11-23 2003-05-29 George Jackowski Plasma protease C1 biopolymer markers predictive of alzheimers disease
JP2005518443A (ja) 2002-02-21 2005-06-23 クォーク バイオテック インコーポレーティッド 脳虚血または脳損傷を予防または治療する方法
CN1300588C (zh) * 2005-02-28 2007-02-14 上海交通大学 用于精神分裂症诊断的血浆特异性蛋白获取方法及应用
GB0701626D0 (en) * 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
EP2370088B1 (fr) 2008-12-27 2016-08-24 Pawan Saharan Nanopeptides dérivés d'un colostrum mammalien pour infections virales et récurrentes à large spectre avec leur procédé d'isolement

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319687B1 (en) * 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
US5767252A (en) * 1996-04-08 1998-06-16 The Johns Hopkins University School Of Medicine Neuronal cell growth factor, Narp
AU4480997A (en) * 1996-09-13 1998-04-02 Mount Sinai School Of Medicine Of The City University Of New York, The Screening methods for compounds useful in the treatment of schizophrenia
WO1998040748A1 (fr) * 1997-03-14 1998-09-17 Neuromark Diagnostic de troubles neurologiques
US5939316A (en) * 1997-03-27 1999-08-17 Millennium Pharmaceuticals, Inc. Chromosome 18 marker
EP1012300A1 (fr) * 1997-09-05 2000-06-28 Acorda Therapeutics Sulfotransferase hnk-1 et ses methodes d'utilisation
NZ503343A (en) * 1997-09-17 2002-09-27 Genentech Inc Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
US6248527B1 (en) * 1998-10-21 2001-06-19 Millennium Pharmaceuticals, Inc. Method of detecting risk of type II diabetes based on mutations found in carboxypeptidase E
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU7508100A (en) * 1999-10-04 2001-05-10 Jens Andersen Human seizure related proteins
EP1101820A1 (fr) * 1999-11-15 2001-05-23 MERCK PATENT GmbH Pentraxin I et recepteur de la pentraxin, inhibiteurs de ces proteines et compositions pharmaceutiques comprenant ces composés

Also Published As

Publication number Publication date
EP1259818A2 (fr) 2002-11-27
WO2001063293A2 (fr) 2001-08-30
WO2001062785A3 (fr) 2002-01-31
WO2001063293A3 (fr) 2002-04-11
AU2001237543A1 (en) 2001-09-03
WO2001062785A2 (fr) 2001-08-30
AU2001233954A1 (en) 2001-09-03
EP1259607A2 (fr) 2002-11-27

Similar Documents

Publication Publication Date Title
WO2002059604A3 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la sclerose en plaques
WO2001075454A3 (fr) Molecules d'acides nucleiques, polypeptides et leurs utilisations pour diagnostic et le traitement de la maladie d'alzheimer notamment
WO2002054081A3 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse renale
ATE342918T1 (de) Genomische sequenz des 5-lipoxygenase- aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma
WO2003028543A3 (fr) Molecules d'acide nucleique, polypeptides et utilisations associees comprenant le diagnostic et le traitement de la maladie d'alzheimer
WO2002082075A3 (fr) Procede de depistage de maladies dementielles chroniques, et peptides et reactifs de depistage correspondants
CA2421007A1 (fr) Procede de detection, dans du plasma ou du serum, d'arn associe a des telomerases htr et htert
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
WO2003087831A3 (fr) Proteines impliquees dans le cancer du sein
BRPI0413495A (pt) reagentes de peptìdeos especìficos para prìons e seus usos
WO2002040702A3 (fr) Methodes de traitement du cancer et d'autres maladies et procedes permettant de developper ces methodes
WO1999047925A3 (fr) Procedes et compositions pour le diagnostic de la polyarthrite rhumatoide
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
WO2005056585A3 (fr) Protéines s du coronavirus du sars et leurs utilisations
WO2001013117A3 (fr) Proteines et genes destines au diagnostic et au traitement du cancer du sein et leur utilisation
WO2002046767A3 (fr) Molecules d'acide nucleique, polypeptides et utilisations associees, parmi lesquelles diagnostic et traitement de la maladie d'alzheimer
WO2001063293A8 (fr) Proteines et genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie
WO2001062784A3 (fr) Proteines
WO2002090974A3 (fr) Procede pour depister une maladie dementielle chronique evolutive, et peptides et reactifs de depistage associes
WO2001063294A3 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de maladies affectives bipolaires (bad) et de depressions unipolaires
WO2001069261A3 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire
WO2003048734A3 (fr) Detection d'arn de metalloproteinase matricielle dans du plasma et du serum
WO2004051269A3 (fr) Proteine de replication
DE60101305D1 (de) Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten
WO2001064876A3 (fr) Gene humain de la schizophrenie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 35/2001 UNDER (30) REPLACE "28.02.2000" BY "28.12.2000"

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001905991

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001905991

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001905991

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP